Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

A novel MYB::PAIP1 oncogenic fusion in pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN) is dependent on BCL2 expression and is sensitive to venetoclax

“…Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematological malignancy with a median survival of 14 months (with a survival window of 6-28 months) from diagnosis. 1 BPDCN is derived from the precursors of plasmacytoid dendritic cells 2 and is recognized as an independent entity of myeloid neoplasms in the 2016 updated World Health Organization classification. 3 Although BPDCN predominantly affects adults with a median age in the 70s, cases involving younger adults and children have been reported.…”